IVI and BBIL launch global Chikungunya vaccine Phase II/III trial in Costa Rica
The International Vaccine Institute (IVI) and Bharat Biotech, funded by the CEPI and Ind- CEPI, have administered the Chikungunya vaccine candidate (BBV87) to the first participant in Phase II/III clinical trial in Costa Rica, launching a multi-country study. This is part of an effort by the CEPI and the Global Chikungunya vaccine Clinical Development Program (GCCDP) to develop and manufacture a Chikungunya vaccine with the aim of equitable access, affordability, and sustainability.
The first participant has been administered Bharat Biotech International Ltd.’s (BBIL’s) Chikungunya vaccine candidate (BBV87) in Phase II/III clinical trial in Costa Rica, launching a study by the International Vaccine Institute (IVI) and BBIL.
Funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the Ind-CEPI initiative, the trial will assess the safety and immunogenicity of the vaccine in healthy adults across multiple countries with endemic Chikungunya. The study advances CEPI’s US $3.5 billion commitment to proactively counter potential pandemics and
epidemics. The CEPI’s funding of up to the US $14.1 million is supported by the European Union’s (EU’s) Horizon 2020 program, and also by a contribution of up to the US $2 million by the Indian Government’s Ind-CEPI initiative.
This is also part of the Global Chikungunya vaccine Clinical Development Program (GCCDP), which works towards an affordable and accessible vaccine to receive WHO prequalification and enable equitable distribution in low- and middle-income countries.
“The IVI-led multi-country scale human trial has begun an important trial phase in furthering
the evaluation of safety and immunogenicity. As a partner, we are committed towards GCCDP’s effort to realize a safe, efficacious vaccine that can help reduce Chikungunya disease burden the world over,” commented Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech.
Dr. Sushant Sahastrabuddhe, Acting Associate Director-General at IVI and Principal Investigator of GCCDP, added that “the start of this trial in Costa Rica is a significant milestone in the effort to make available a safe, effective, and affordable Chikungunya vaccine for the one billion people around the world at risk of Chikungunya virus infection.”
“Chikungunya is a debilitating illness that results in substantial health and economic consequences around the world, including in low- and middle-income countries. Our modern ways of living, globalization, vector adaptation and climate change could also threaten to advance the spread of the disease further, putting more of the global population at risk.”
About BBV87 vaccine candidate
BBIL’s BBV87 vaccine is an inactivated whole virion vaccine, a technology with a unique safety profile that makes it accessible to special populations, such as immunocompromised or pregnant women. The vaccine is based on a strain derived from an East, Central, South African (ECSA) genotype, and has completed standard pre-clinical
About International Vaccine Institute (IVI) The International Vaccine Institute (IVI) is a non-profit intergovernmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP), with a mandate to make vaccines available and accessible for the world’s most vulnerable people. IVI focuses on infectious diseases of global health. It has 36 countries and the World Health Organization (WHO) on its treaty, including the Republic of Korea, Sweden, India,
and Finland as state funders. For more information, visit https://www.ivi.int.
About Bharat Biotech
Located in Hyderabad, India, Bharat Biotech has an impressive track record of innovation and a vast product portfolio. It has administered over 4 billion doses of vaccines worldwide and is leading innovation with the development of vaccines for multiple infectious diseases. For more information, visit www.bharatbiotech.com.
CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, to develop vaccines against future epidemics. It has over 20 vaccine candidates in development and has invested in new platform technologies to develop vaccines against unknown pathogens.
CEPI has initiated multiple programs to develop vaccines against SARS-CoV-2 and its variants, leveraging the rapid response platforms developed by its partners. It is committed to supporting the development of safe and effective COVID-19 candidates and enabling equitable distribution of these vaccines through COVAX. CEPI’s 5-year-plan is available at endpandemics.cepi.net.